Vifor Pharma’s Ferinject granted new recommendations in updated 2021 ESC heart failure guidelines - Seite 2

The ESC HF guidelines aim to provide practical, evidence-based recommendations for the diagnosis and treatment of HF, thereby improving and harmonizing standards of diagnosis and treatment of cardiovascular diseases for physicians, and potentially optimizing patient care. The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021.

The 2021 ESC guidelines are published under: www.escardio.org/Guidelines

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

About AFFIRM-AHF
The AFFIRM-AHF study was a multi-center, randomized, double-blind, placebo-controlled trial, comparing the effect of intravenous ferric carboxymaltose (FCM) on hospitalizations and mortality in iron deficient patients admitted for acute heart failure. The study demonstrated that administration of Ferinject reduced the risk of HF hospitalizations and improved quality of life with no apparent effect on the risk of cardiovascular death.

About Ferinject
Ferinject/Injectafer (ferric carboxymaltose) is a leading i.v. iron therapy with market authorization in 84 countries by the end of June 2021. More than 16 million patient years of experience have helped to establish Ferinject/ Injectafer as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data².

About Veltassa
Veltassa (patiromer) is a potassium binder approved for the treatment of hyperkalemia. Veltassa was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium. Veltassa should not replace emergency treatment for life-threatening hyperkalemia.

References:
¹ Anker, S.,D. (2018). Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient meta-analysis. Eur J Heart fail. 20(1):125-133. doi: 1002/ejhf.823.
² Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005519/en/